Breaking News

Anavex Secures cGMP Manufacture for ANAVEX Trials

July 21, 2014

Phase IIa trial scheduled for 2014

Anavex Life Sciences Corp. has secured cGMP manufacture of ANAVEX 2-73 for its clinical trial supplies. Further details were not disclosed.
 
"We are delighted to have the active drug product (API) manufactured and available for our Phase IIa trial," said Christopher U. Missling, PhD, president and chief executive officer of Anavex. "We look forward to initiating clinical trials with ANAVEX PLUS for the treatment of Alzheimer's disease, which remains on track to commence in 2014 with data from the first part of the trial expected to be reported in mid 2015.”
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials